Top

Cancer Immunology, Immunotherapy

Published in:

01-10-2013 | Original Article

Dendritic cell phenotype can be improved by certain chemotherapies and is associated with alterations to p21^waf1/cip1

Authors: Wai Man Liu, Katherine Ann Scott, Mareike Thompson, Angus George Dalgleish

Published in: Cancer Immunology, Immunotherapy | Issue 10/2013

Abstract

Introduction

Dendritic cells (DCs) possess the capacity to elicit immune responses against harmful antigens and have been used in DC-vaccines to stimulate the immune system to engage cancer cells. However, a lack of an appreciation of the quality of the DC that is used and/or the monocyte from which it is derived has limited their successful incorporation into treatment strategies.

Methods

In the current study, we explored the relationship between cytokine receptor expression on the monocytes and its subsequent development into DCs. The significance of p21 expression in DCs during differentiation was also studied, as was the effect that manipulating this with chemotherapy may have on DC quality.

Results

DCs separated into two groups based on their ability to respond to a maturation stimulus. This quality correlated with a particular receptor profile of granulocyte–macrophage colony-stimulating factor and interleukin 4 expressed on the monocytes from which they were derived. DC quality was also associated with p21 expression, and artificially increasing their levels in DCs by using some chemotherapy improved function.

Conclusions

Overall, these studies have highlighted a role for common chemotherapy in activating p21 in DCs, which is a prerequisite for good DC function.

Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480–489PubMedCrossRef

Palucka K, Ueno H, Banchereau J (2011) Recent developments in cancer vaccines. J Immunol 186(3):1325–1331PubMedCrossRef

Dalgleish AG (2011) Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 29(47):8501–8505PubMedCrossRef

Liu WM, Dalgleish AG (2012) The potential beneficial effects of drugs on the immune response to vaccination. Semin Oncol 39(3):340–347PubMedCrossRef

Liu WM, Dennis JL, Fowler DW, Dalgleish AG (2012) The gene expression profile of unstimulated dendritic cells can be used as a predictor of function. Int J Cancer 130(4):979–990PubMedCrossRef

Lanza F, Castagnari B, Rigolin G, Moretti S, Latorraca A, Ferrari L, Bardi A, Castoldi G (1997) Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts, and normal hemopoietic cells. Leukemia 11(10):1700–1710PubMedCrossRef

Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE (1999) The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17:701–738PubMedCrossRef

Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501–1512PubMedCrossRef

Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672–1677PubMedCrossRef

10.

Coqueret O (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13(2):65–70PubMedCrossRef

11.

Santiago-Raber ML, Lawson BR, Dummer W, Barnhouse M, Koundouris S, Wilson CB, Kono DH, Theofilopoulos AN (2001) Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 167(7):4067–4074PubMed

12.

Jackson SK, DeLoose A, Gilbert KM (2001) Induction of anergy in Th1 cells associated with increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. J Immunol 166(2):952–958PubMed

13.

Gazitt Y, Reddy SV, Alcantara O, Yang J, Boldt DH (2001) A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myristate acetate. J Cell Physiol 187(1):124–135PubMedCrossRef

14.

Kramer JL, Baltathakis I, Alcantara OS, Boldt DH (2002) Differentiation of functional dendritic cells and macrophages from human peripheral blood monocyte precursors is dependent on expression of p21 (WAF1/CIP1) and requires iron. Br J Haematol 117(3):727–734PubMedCrossRef

15.

Jonuleit H, Kühn U, Müller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27(12):3135–3142PubMedCrossRef

16.

Liu WM, Fowler DW, Smith P, Dalgleish AG (2010) Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102(1):115–123PubMedCrossRef

17.

Tuana G, Volpato V, Ricciardi-Castagnoli P, Zolezzi F, Stella F, Foti M (2011) Classification of dendritic cell phenotypes from gene expression data. BMC Immunol 12:50–62PubMedCrossRef

18.

Shortman K, Naik SH (2007) Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 7(1):19–30PubMedCrossRef

19.

Guthridge MA, Powell JA, Barry EF, Stomski FC, McClure BJ, Ramshaw H, Felquer FA, Dottore M, Thomas DT, To B, Begley CG, Lopez AF (2006) Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J 25(3):479–489PubMedCrossRef

20.

Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179(4):1109–1118PubMedCrossRef

21.

Roy KC, Bandyopadhyay G, Rakshit S, Ray M, Bandyopadhyay S (2004) IL-4 alone without the involvement of GM-CSF transforms human peripheral blood monocytes to a CD1a(dim), CD83(+) myeloid dendritic cell subset. J Cell Sci 117(16):3435–3445PubMedCrossRef

22.

Conti L, Cardone M, Varano B, Puddu P, Belardelli F, Gessani S (2008) Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur J Immunol 38(3):750–762PubMedCrossRef

23.

Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11):2326–2335PubMedCrossRef

24.

Motoshima H, Goldstein BJ, Igata M, Araki E (2006) AMPK and cell proliferation–AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574(1):63–71PubMedCrossRef

25.

Lee KM, Jo S, Kim H, Lee J (1813) Park CS (2011) Functional modulation of AMP-activated protein kinase by cereblon. Biochim Biophys Acta 3:448–455

26.

Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, Galustian C (2013) Enhanced cross-priming of naive CD8+ T cells by DCs treated by the IMiDs^® immunomodulatory compounds Lenalidomide and Pomalidomide. Immunology. doi:10.1111/imm.12087

27.

Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105(7):2862–2868PubMedCrossRef

28.

Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11(18):6713–6721PubMedCrossRef

Title: Dendritic cell phenotype can be improved by certain chemotherapies and is associated with alterations to p21waf1/cip1
Authors: Wai Man Liu
Katherine Ann Scott
Mareike Thompson
Angus George Dalgleish
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 10/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-013-1456-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2013

Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer

Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications

Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients

DEAD/H (Asp–Glu–Ala–Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells

Empty liposomes induce antitumoral effects associated with macrophage responses distinct from those of the TLR1/2 agonist Pam3CSK4 (BLP)

Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer